ArticleChemistry & biodiversity2026
Westersidones A-C: Antimicrobial Depsidones From the Deep-Sea Cold Seep-Derived Endozoic Fungus Westerdykella dispersa CS-734.
Article in Chemistry & biodiversity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Eight depsidone derivatives (1-8), including three new compounds designated as westersidones A-C (1-3), were isolated from Westerdykella dispersa CS-734, an endozoic fungus derived from the deep-sea cold seep mussel Gigantidas platifrons. Their structures were elucidated through extensive spectroscopic analysis, including HRESIMS, NMR, and single-crystal X-ray diffraction. Remarkably, compound 1 represents a rare and unprecedented hybrid natural product formed by the fusion of a depsidone and a naphtho-γ-pyrone skeleton. The antibacterial activities against human and aquatic pathogens of the isolated compounds were assayed. Notably, compound 8 exhibited the most potent activity against several tested strains, with MICs 4-16 µg/mL, underscoring the critical role of the C-4 aldehyde group in enhancing antimicrobial potency.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.